Gene therapy: Edexcel AS Biology Unit 1 guide

This work has been verified by our teacher: 17.01.2026 at 6:40

Homework type: Essay

Added: 17.01.2026 at 6:09

AS Edexcel Biology Unit 1: Gene Therapy

Types of Gene Therapy: Approaches and Aims

Gene therapy methodologies can be further subdivided by how the genetic material is manipulated. Gene addition introduces a functional copy of a gene to supplement or replace the activity of a faulty allele. Gene replacement or editing seeks to correct, rather than simply supplement, a mutated gene sequence, such as by cutting out a mutation and inserting the correct code—an ability sharply enhanced by genome editing technologies like CRISPR-Cas9. In contrast, gene silencing focuses on reducing the activity of problematic genes, often using RNA interference (RNAi) or antisense oligonucleotides to block production of harmful proteins. Each approach aims either to restore normal protein function, reduce toxic protein accumulation, or selectively kill problematic cells, such as cancerous ones.

Delivery Systems: Molecular Methods and Mechanisms

Retroviruses and their modified kin, lentiviruses, can integrate their payload permanently into the host genome, affording stable, long-term gene expression—an invaluable trait for diseases affecting dividing cells, such as many blood disorders. However, integration can come with the risk that inserted genes disrupt essential host genes, potentially triggering cancer (insertional mutagenesis). Adenoviruses, by contrast, generally deliver genes as stable, extrachromosomal elements; their gene expression is typically transient, lasting days to weeks, and they can provoke robust immune responses, which may limit their clinical utility or even endanger patients. The adeno-associated virus (AAV) is a newer viral vector, notable for its low immunogenicity and good safety record, though it is constrained by a limited 'cargo' capacity, making it unsuitable for large genes (such as the dystrophin gene in Duchenne muscular dystrophy).

In its simplest configuration, viral gene therapy involves removing pathogenic genes from the virus, inserting a therapeutic transgene, amplifying viral particles in the laboratory, and then administering these to the patient, either directly or via ex vivo modified cells.

Alongside viral vectors, non-viral approaches are increasingly explored to circumvent immune and safety issues. Liposomes—tiny synthetic vesicles crafted from lipids—can encapsulate DNA or RNA, merge with cell membranes, and release their genetic payloads intracellularly. Electroporation employs brief electrical pulses to open temporary pores in cell membranes, allowing genetic material to enter, and is especially useful for cells manipulated outside the body. More experimental methods include direct injection of 'naked' DNA, polymer-based carriers, or biolistic 'gene guns'—though these often suffer from low efficiency or tissue damage.

Of especial significance in recent years are genome editing technologies, in particular CRISPR-Cas9. Here, a short RNA guide sequence steers the Cas9 enzyme precisely to a mutation site in the DNA, where the machinery enacts a double-stranded cut. The resulting break can then be used either to disrupt (knock out) a gene or—if supplied with a correct template—to repair the sequence. Sophisticated refinements like base editors and prime editing allow specific base alterations without cutting both DNA strands, potentially reducing harmful off-target effects.

Central to all these technologies are elements such as promoters (which direct gene expression in specific cell types), regulatory sequences, and careful optimisation of genetic cargo size to fit the chosen vector. Tropism—the preference of a vector for infecting certain cell types—must be matched to the therapeutic goal.

*Diagram suggestion*: A labelled schematic contrasting (a) a retroviral vector integrating into a chromosome, (b) a liposome fusing with the membrane and releasing DNA, and (c) the CRISPR-Cas9 system cutting DNA.

Ex Vivo versus In Vivo Gene Therapy

By comparison, in vivo gene therapy entails delivering the therapeutic agent directly into the patient, whether intravenously, via injection into a specific tissue, or by inhalation for the respiratory tract. This route is necessary for diseases where key tissues (such as lung epithelial cells in cystic fibrosis, or photoreceptors in inherited blindness) are not accessible ex vivo. However, this approach exposes the patient to systemic risks, including immune attacks, and offers less control over exactly which cells express the introduced gene.

Key Case Studies and Real-World Applications

In cystic fibrosis (CF), a rare but deadly condition caused by mutations in the CFTR gene (affecting chloride ion transport and leading to thick airway mucus), many early UK-led trials delivered normal CFTR genes to airway cells using either adenoviral or liposomal vectors, sometimes via inhaled aerosols. Despite initial promise, progress has been hampered by difficulties in delivering DNA through sticky mucus and producing enough protein to relieve symptoms, illustrating the formidable barriers still at play.

A distinct success story is found in ADA-SCID (adenosine deaminase deficiency – severe combined immunodeficiency), a disorder where children lack key immune cells. Here, ex vivo retroviral gene therapy enables doctors to restore healthy immune function by modifying the patient’s own haematopoietic stem cells. Notably, babies treated in specialist centres (including Great Ormond Street Hospital in London) were able to develop effective immune defences and live healthy lives.

A more recent breakthrough is Luxturna (voretigene neparvovec), the first approved in vivo gene therapy in the UK for people with inherited retinal dystrophy caused by RPE65 mutations. Using AAV vectors injected directly into the retina, patients experience measurable improvements in sight—a striking example of gene therapy's direct clinical impact.

Additional advances are evident in CAR-T cell therapy, where a patient's T lymphocytes are engineered ex vivo to express synthetic receptors that recognise and destroy cancerous cells. Following regulatory approval by the NHS in 2018, such therapies are now available for certain leukaemias and lymphomas, albeit at considerable financial cost.

Nevertheless, there have also been tragedies: in 1999, a young American, Jesse Gelsinger, died of an overwhelming immune reaction to an adenovirus vector during an experimental trial; and in some retroviral SCID trials, children developed leukaemia due to mutated DNA sequences, highlighting the delicate balance between benefit and risk.

Evaluating Scientific Benefits

Scientific evaluation of gene therapies revolves around metrics including the degree to which normal protein function is restored, the level and durability of clinical improvement, and whether gene expression is maintained safely over time. Rigorous monitoring for unintended effects (such as immune responses or genetic instability) is an essential part of all ongoing trials. While optimism is justified, it must be tempered by the reality that most therapies are at an early, experimental stage and success stories remain the exception not the rule.

Risks, Technical Limitations and Scientific Challenges

Other risks arise from the technology itself. Insertional mutagenesis—where a vector inserts genetic material into a harmful spot in the genome—can transform healthy cells into malignant ones, a problem tragically encountered in early SCID gene therapy trials. Off-target editing, particularly with CRISPR, threatens to alter DNA in unexpected ways, causing unintended consequences.

Physical barriers to successful delivery are also significant: for instance, thickened mucus in CF lungs impedes vector access to target cells; similarly, the formidable blood-brain barrier prevents easy delivery to neural tissues, limiting progress against neurological diseases. Size constraints of vectors mean some genes can't be delivered by the safest or most efficient means.

Further, the duration and regulation of expression can be unpredictable—most non-integrating vectors only produce temporary effects, while integrating vectors face safety challenges. Finally, the cost and technical complexity of producing personalised gene therapies remains exorbitant, raising concerns about their scalability and fairness of access within national health services such as the NHS.

Scientists are actively seeking solutions: improved vector design (e.g. using less immunogenic AAVs), cell-specific promoters to limit where genes are expressed, integrase-deficient viral systems for safer editing, and the exploration of non-viral nanoparticles show promise for the future.

Ethical, Legal and Social Implications

Consent and autonomy represent further challenges: children and embryos cannot consent to experimental interventions, requiring careful legal and medical review. Equitable access is also pressing—the prospect of 'miracle cures' being limited to those who can pay, within or outside the NHS framework, risks widening social divides.

Distinct boundaries must be drawn between therapy—to restore health—and enhancement, where genetic modification could in principle be used to select traits such as intelligence or physique, leading to ethical unease about 'designer babies.'

Animal studies, although vital for safety and efficacy, raise separate ethical issues, balancing scientific progress against animal welfare. Clinical trials in humans demand robust informed consent, lifelong monitoring, and independent regulatory scrutiny, roles fulfilled in the UK by bodies such as the MHRA and RECs.

Conclusion

---

Appendix: Key Diagrams, Terminology, and Exam Tips

- Glossary of Key Terms: - Somatic gene therapy: modification of non-reproductive cells; not passed on to offspring. - Germline gene therapy: modification of gametes/embryos; heritable. - Vector: vehicle used to deliver genetic material. - Retrovirus, adenovirus, AAV: types of viral vectors. - Liposome: lipid-based carrier for genetic material. - Electroporation: use of electricity to introduce DNA/RNA into cells. - CRISPR-Cas9: gene editing tool for precise DNA modification. - Insertional mutagenesis: genetic insertion event leading to disruption of host genes. - Off-target effects: unintended genetic modifications. - Tropism: vector preference for infecting specific cell types. - Promoter: DNA sequence controlling gene expression.

- Exam Technique Tips: - Begin with a clear introduction and structure paragraphs by theme (mechanism, benefits, risks, ethics). - Employ clear transitions: “Firstly”, “In contrast”, “Moreover”, “Therefore”. - Support points with relevant, accurate examples—preferably those well-known in British clinical practice. - Avoid overstatement and clearly distinguish between current realities and future potential. - Address both ethical and scientific considerations for the fullest credit.

Further Reading

By adhering to these principles—clearly conveying the science, using apt UK-relevant examples, and taking a balanced evaluative stance—students can structure high quality, nuanced, and exam-ready essays on gene therapy.